Psychotropic medications in children with autism spectrum disorders: a systematic review and synthesis for evidence-based practice.

The team hunted for every randomized trial that tested a psychotropic drug in autistic children. They found 33 studies published through 2011. Two reviewers graded each trial for quality and pulled out the numbers on core ASD symptoms, irritability, hyperactivity, and repetitive behavior.

Only two drugs had solid evidence: risperidone and aripiprazole cut severe tantrums, aggression, and self-injury. Everything else—SSRIs, stimulants, sleep meds—rested on one or two small, short studies. For social or communication targets, no pill reached the ‘works’ bar.

Smith et al. (2010) counted kids first: a large share of 5,000 registry children were already on at least one psychotropic. Hudson et al. (2012) then asked, ‘But do these drugs actually work?’ The pair shows high real-world use racing ahead of weak evidence.

Brondino et al. (2016) zoomed in on GABA drugs (valproate, arbaclofen). They also found ‘not enough proof,’ backing the target review’s wider ‘thin evidence’ picture.

Li et al. (2025) looked at Chinese in-patients and saw a large share on meds, with kids who have ID getting more antipsychotics and poly-pharmacy. This extends the warning: once a child is hospitalized, prescribing leaps far beyond the small evidence base Matthew flagged.

Before you recommend or monitor any pill, pull this chart: only risperidone and aripiprazole have strong RCT support for irritability. Every other prescription is an experiment. Use the gap to keep behavioral programming in the lead and to document informed consent when meds are trialed off-label.